Pharma giant Pfizer (NYSE: PFE) released its second-quarter earnings report on July 28, and the results were impressive. Naturally, the big story surrounded the drugmaker's COVID-19 vaccine, BNT162b2, whose revenue came in at $7.8 billion for the period. BNT162b2 is the gift that keeps on giving, and Pfizer now expects total revenue of $33.5 billion from the vaccine this year, which is up from its previous guidance of $26 billion.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting